Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CorMedix Inc. - Common Stock (NQ:CRMD)

9.970 -1.270 (-11.30%)
Streaming Delayed Price Updated: 2:39 PM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CorMedix Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
News headline image
Applied Materials To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
CorMedix Lifts Q2 Outlook As Dialysis Partner Expands DefenCath Use; Needham Raises PT To $20 ↗
DefenCath, CorMedix’s lead product, was launched in hospitals in April 2024 and in outpatient settings in July 2024 following FDA approval. 
Via Stocktwits
News headline image
Earnings Scheduled For May 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Preview For Cormedix ↗
 
Via Benzinga
News headline image
CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading Drug ↗
CorMedix shares bounded to a four-year high Monday after the biotech company inked an expanded deal for its leading drug. 
Via Investor's Business Daily
News headline image
CorMedix Stock Hits New 52-Week High On Updated Guidance: The Details ↗
CorMedix Inc (NASDAQ:CRMD) shares are hitting new 52-week highs on Monday after the company raised its sales guidance for the second quarter. 
Via Benzinga
News headline image
Kroger Posts Better-Than-Expected Earnings, Joins Couchbase, CarMax And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
CorMedix Q1 Earnings Trump Estimates: Retail’s Overjoyed ↗
The company reported net revenue of $39.1 million for the first quarter from the sales of DefenCath, above an analyst estimate of $36, as per Finchat data. 
Via Stocktwits
Topics Earnings Government
News headline image
CorMedix Stock Rises After Preliminary Q1 Results Exceeds Expectations: Retail’s Elated ↗
The company expects quarterly adjusted earnings before interest, taxes, depreciation, and amortisation (EBITDA) to exceed $22.5 million once final numbers are reported, exceeding expectations of $14.78... 
Via Stocktwits
News headline image
Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is Investigating CorMedix Inc. on Behalf of CorMedix Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
CorMedix (CRMD) Q4 2024 Earnings Call Transcript ↗
CRMD earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Which stocks are experiencing notable movement on Tuesday? ↗
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
News headline image
CorMedix Stock Loses Almost A Third Of Its Market Cap After Downbeat H1 Revenue Outlook – But Retail Shrugs It Off ↗
The company reported earnings of $0.22 per share compared with a loss of $0.26 per share in the corresponding period of 2023, owing to the launch of its lead product, DefenCath. 
Via Stocktwits
News headline image
Nasdaq Gains 50 Points; US New Home Sales Rise In February ↗
 
Via Benzinga
News headline image
Which stocks are moving before the opening bell on Tuesday? ↗
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
Earnings Scheduled For March 25, 2025 ↗
 
Via Benzinga
News headline image
CorMedix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗
 
Via Benzinga
News headline image
Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Healthcare Stocks Doing Well But SMID Biotech Looking A Little Frazzled ↗
Small caps took another step down this past week as geopolitical events dampened sentiment. 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
3 Value Stocks That Are Backed By The World’s Largest Activist Hedge Fund ↗
Sometimes, hedge funds make risky decisions. But these stocks are at the lower end of the exposure risk spectrum. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Top movers in Friday's after hours session ↗
As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Elliott Investment Management Buys Wolfspeed Stock, Bets Against Nvidia In Q4 ↗
Elliott Investment Management made several portfolio moves in the fourth quarter, closing multiple options positions and shaking up the activist firm's technology exposure. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Two Big Weeks To Play A Rally In Biotech And Healthcare Stocks ↗
The healthcare sector is lagging over the past year and recent quarter with the XLV flat for 2024 and down over 4% for the recent quarter. 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
Smaller Cap Biotechs Are In Season: How Are We Doing? ↗
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range. 
Via Talk Markets
News headline image
CorMedix (CRMD) Q3 2024 Earnings Call Transcript ↗
CRMD earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.